» Brain Cancer

Brain Cancer

CDX 110-04: An International, Randomized, Double-Blind, Controlled Study of  Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The “ACT IV” Study)
The purpose of this research study is to find out whether adding treatment with rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug called temozolomide helps to shrink brain tumors or prevents brain tumors from growing and helps patients with brain tumors live longer than treatment with temozolomide alone.
Principal Investigator: Dr. Peter Graze, MD. (443)-573-5300
Research Staff: Elizabeth Egan, R.N. (443) – 481-5811
                           Emily Ross, CRCC (443) – 481- 4392

Our Studies